Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous
NMR in Biomedicine · 2024-04 · 37 (4)
DOI: 10.1002/nbm.5095 ↗Kurz gefasst
Fachartikel in der Zeitschrift NMR in Biomedicine, online erschienen am 11.01.2024. Verfasst von Gülnur Ungan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Biomédica en Red (CIBER), Madrid, Spain. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), H2020-EU.1.3. EXCELLENT SCIENCE-Marie Skłodowska-Curie Actions, Instituto de Salud Carlos III (ISCIII), Proyectos de investigación en salud 2020.
Abstract (Originalsprache)
The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow‐up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast‐enhancing regions may appear that can correspond to true progression or pseudoprogression. We retrospectively evaluated 31 consecutive patients at the first follow‐up after concomitant treatment to check whether the metabolic pattern assessed with multivoxel MRS was predictive of treatment response 2 months later. We extracted the underlying metabolic patterns of the contrast‐enhancing regions with a blind‐source separation method and mapped them over the reference images. Pattern heterogeneity was calculated using entropy, and association between patterns and outcomes was measured with Cramér's V . We identified three distinct metabolic patterns—proliferative, necrotic, and responsive, which were associated with status 2 months later. Individually, 70% of the patients showed metabolically heterogeneous patterns in the contrast‐enhancing regions. Metabolic heterogeneity was not related to the regions' size and only stable patients were less heterogeneous than the rest. Contrast‐enhancing regions are also metabolically heterogeneous 1 month after concomitant treatment. This could explain the reported difficulty in finding robust pseudoprogression biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación Biomédica en Red (CIBER), Madrid, Spain.
- Departament de Bioquímica i Biologia Molecular and Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
- Grup de Neuro-oncologia, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain.
- Data Science Research Centre, Liverpool John Moores University (LJMU), Liverpool, UK.
- IDEAI-UPC Research Center, UPC BarcelonaTech, Barcelona, Spain.
ORCID-Profile: Gülnur Ungan, Albert Pons-Escoda, Daniel Ulinic, Carles Arús, Sandra Ortega-Martorell, Ivan Olier, Alfredo Vellido, Carles Majós, Margarida Julià-Sapé
Förderung
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
- H2020-EU.1.3. EXCELLENT SCIENCE-Marie Skłodowska-Curie Actions
- Instituto de Salud Carlos III (ISCIII), Proyectos de investigación en salud 2020
- Spanish Ministerio de Economía y Competitividad
- Spanish AEI
- Generalitat de Catalunya, Xartecsalut
- Agencia Estatal de Investigación
Zitieren
APA
Ungan, G., Pons-Escoda, A., Ulinic, D., Arús, C., Ortega-Martorell, S., Olier, I., Vellido, A., Majós, C., & Julià-Sapé, M. (2024). Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous. NMR in Biomedicine, 37(4). https://doi.org/10.1002/nbm.5095
Vancouver
Ungan G, Pons-Escoda A, Ulinic D, Arús C, Ortega-Martorell S, Olier I, et al. Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous. NMR in Biomedicine. 2024;37(4). doi:10.1002/nbm.5095
BibTeX
@article{Ungan2024,
author = {Ungan, Gülnur and Pons-Escoda, Albert and Ulinic, Daniel and Arús, Carles and Ortega-Martorell, Sandra and Olier, Ivan and Vellido, Alfredo and Majós, Carles and Julià-Sapé, Margarida},
title = {Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous},
journal = {NMR in Biomedicine},
year = {2024},
volume = {37},
number = {4},
doi = {10.1002/nbm.5095}
}
EUVIMED